Stocks
RBC Capital Raises Johnson & Johnson Price Target to $290
RBC Capital analyst Shagun Singh has increased the price target for Johnson & Johnson (NYSE: JNJ) from $287.00 to $290.00. This adjustment reflects a modest upward revision in the firm's outlook for the healthcare giant.
The new price target was announced on October 6, 2026, indicating continued confidence in JNJ's performance. While the full details of the analysis remain behind a premium paywall, the updated target suggests positive sentiment from the analyst.
This is a premium-only article on StreetInsider.com, requiring a subscription or free trial to access the complete rationale behind the price target change.